Document is current
Any future updates will be listed below
-
Authors
Kitson, Geoff
Byford, Marion
Cass, Lindsey
Howat, David
Köhn, Brigitte
Bisquera, Alessandra
Catchpole, Andrew
Noulin, Nicolas
Thomson, Douglas https://orcid.org/0009-0005-1838-2072
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05507567 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge
https://doi.org/10.1007/s40121-025-01179-2
-
Funding
Funding for this research was provided by:
Pneumagen Ltd
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 3 June 2025
First Online: 2 July 2025
Declarations
:
: Geoff Kitson, Lindsey Cass, Douglas Thomson, Brigitte Köhn are contracted by Pneumagen Ltd. Alessandra Bisquera, Marion Byford, Andrew Catchpole, David Howat, Nicholas Noulin were previously contracted to Pneumagen Ltd.
: The protocol for this study was approved by South Central—Berkshire B Research Ethics Committee (REC reference 22/SC/0223), and the study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. Informed consent to voluntarily participate in the investigation was obtained from all participants, and investigators were responsible for ensuring all participants understood the informed consent form (ICF). Participants were aware that they could withdraw from the study at any time, for any reason, and without prejudice to their future medical care. Participants consented to dissemination and publication of data from the study, with the assurance that all data would be handled in accordance with local data protection law.
